Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 01-Jul 2024. Module: IPS terminology module (core metadata concept)
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3767988015 | Carbidopa anhydrous | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | IPS terminology module (core metadata concept) |
| 3767989011 | Carbidopa anhydrous (substance) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | IPS terminology module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Carbidopa anhydrous | Is a | Amine and/or amine derivative | true | Inferred relationship | Some | ||
| Carbidopa anhydrous | Is a | Central nervous system agent (substance) | true | Inferred relationship | Some | ||
| Carbidopa anhydrous | Is a | Receptor agonist | true | Inferred relationship | Some | ||
| Carbidopa anhydrous | Has disposition (attribute) | Receptor agonist (disposition) | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Product containing precisely carbidopa anhydrous (as carbidopa) 10 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | True | Carbidopa anhydrous | Inferred relationship | Some | 2 |
| Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 250 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | True | Carbidopa anhydrous | Inferred relationship | Some | 2 |
| Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg oral tablet | Has basis of strength substance (attribute) | True | Carbidopa anhydrous | Inferred relationship | Some | 2 |
This concept is not in any reference sets
FHIR